Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5972423 | 0.88 | TRPV1 (0.51) | NR1H4EPHX2HDAC3HDAC8HDAC6 | |
| SCHEMBL5972503 | 0.86 | ESRRB (0.48) | NR1H4EPHX2 | |
| SCHEMBL3928617 | 0.82 | ALDH1A1 (0.59) | NR1H4EPHX2MEN1KMT2ACYP2C19 | |
| SCHEMBL2246757 | 0.81 | PDE2A (0.46) | EPHX2MEN1KMT2ARAB9ALMNA | |
| SCHEMBL27400013 | 0.77 | IMPDH2 (0.51) | NR1H4EPHX2MEN1KMT2ARAB9A | |
| SCHEMBL5973321 | 0.77 | MAPT (0.67) | HDAC3HDAC8HDAC6MEN1KMT2A | |
| SCHEMBL4132019 | 0.77 | TRPV1 (0.56) | — | |
| SCHEMBL27402401 | 0.77 | METTL3 (0.49) | HDAC3HDAC8HDAC6MEN1KMT2A | |
| SCHEMBL10209975 | 0.76 | L3MBTL1 (0.47) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL5972600 | 0.76 | HDAC3 (0.54) | HDAC3HDAC8HDAC6KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004133-A1 | Modulators of VR1 receptor | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004133-A1 | Modulators of VR1 receptor | TRPV1, TRPV2, TRPV3 | NR1H4 417/4885EPHX2 3832/4885HDAC3 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.